-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Amyloid Beta Protein
Cerebral Amyloid Angiopathy (JGCR)
Summary Cerebral Amyloid Angiopathy (CAA) is characterised mainly by impaired perceptual speed, episodic memory, semantic memory, attention and executive function. It has much in common with global cognitive impairment, and diagnosis may overlap with that for Alzheimer’s Disease or other … Continue reading
Posted in Depression, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Mental Health, Quick Insights, Universal Interest
Tagged Ageing Population, Amyloid, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β Protein, Boston Radiological Criteria for Probable CAA, Cerebral Amyloid Angiopathy, Cerebral Amyloid Angiopathy (CAA), Cerebral Amyloid Angiopathy (CAA): Clinical Manifestations, Cerebral Amyloid Angiopathy (CAA): Psychiatric Manifestations, Cerebral Amyloid Angiopathy (CAA): Psychopathology, Cerebral Amyloid Angiopathy: Neuropsychiatric Patterns, Cerebral Amyloid Angiopathy: Psychiatric Presentations in Old Age, Cognitive Impairment, Computed Tomography (CT) Scan, Dementia and Cognitive Impairment, Differential Diagnosis, Impulsivity, Journal of Geriatric Care and Research (JGCR), Magnetic Resonance Imaging (MRI) Scan, Neurodegenerative Diseases, Neurodegenerative Disorders, New Zealand, Waitemata District Health Board (Auckland)
Leave a comment
Blood Test Able to Predict Alzheimer’s Disease Decades Before Symptoms? (BBC News / Neurology)
Summary Research published in the Neurology journal claims a significant breakthrough in the development of a blood test (for plasma Aβ42/Aβ40) which may be able to predict Alzheimer’s Disease onset with 94% accuracy. Due caution: “But it’s important to note … Continue reading
Posted in BBC News, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Quick Insights, Universal Interest
Tagged Alzheimer's Disease: Diagnosis, Alzheimer’s Early Screening, Amyloid, Amyloid and Tau PET, Amyloid Beta, Amyloid Beta (Aβ42 and Aβ40), Amyloid Beta Protein, Amyloid-β (Aβ), Amyloid-β Protein, BBC Health News, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood Test for Brain Amyloidosis: Validated Using Amyloid PET and CSF p-tau181/Aβ42 as Reference Standards, Blood Tests, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brain Imaging, Brain Research, Case Finding, Conversion to Dementia From Prodromal Disease, Dementia Diagnosis, Dementia Innovation, Dementia Research, Dementia Screening, Department of Neurology: Washington University, Diagnosis, Diagnosis of Alzheimer's Disease, Diagnostic Imaging, Division of Biostatistics: Washington University, Drug Development for Alzheimer's Disease, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Hope Center for Neurological Disorders: Washington University, Knight Alzheimer's Disease Research Center: Washington University, Mallinckrodt Institute of Radiology: Washington University, Neurology (Journal), Non-Invasive Biomarkers, Plasma Biomarkers, Plasma β-Amyloid 42/40, Plasma Protein Markers of MRI Measures in Asymptomatic Individuals, Preclinical Alzheimer's Disease, Preclinical Biomarkers in Alzheimer's Disease, Predictive Ability (of Tests), Prodromal Alzheimer's Disease, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Rapid Screening, Recruitment Onto Dementia Clinical Trials, SAP (Protein), SAP: Serum Amyloid Protein, Screening, Screening for Dementia, Washington University School of Medicine
Leave a comment
Further Evidence on the Association Between Poor Oral Health and the Risk of Developing Alzheimer’s Disease. New Possibilities for Treatment? (BBC News / Science Advances)
Summary Analysis of brain tissue, spinal fluid, and saliva from persons with Alzheimer’s Disease indicates the presence of Porphyromonas gingivalis (the bacterium associated with chronic gum disease) in the brain and central nervous system. Animal research using mice indicates that … Continue reading
Posted in Animal Studies, BBC News, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, Universal Interest
Tagged Alzheimer's Disease and Chronic Periodontitis, Alzheimer's Disease Causation and Possible Treatments, Alzheimer’s Disease, Amyloid Beta, Amyloid Beta Protein, Arginine-Gingipain A (RgpA), Arginine-Gingipain B (RgpB), Australia, Bazian, Behind the Headlines, Beta-Amyloid Plaques, Chronic Gum Disease, Chronic Periodontitis, Common Oral Problems and Risk Factors, COR271, COR388, Cortexyme, Dementia Risk Factors, Dental Healthcare, Dental Hygiene, Evidence for Risk Factors of Dementia, Gingipain, Gingipain Inhibitors, Gum Disease, Gum Disease (Periodontitis), Gum Disease Bacteria, Harvard University School of Dental Medicine, β-Amyloid Plaques, Jagiellonian University (Poland), Lysine-Gingipain (Kgp), Mice, Modifiable Risk Factors, Neuroprotective Agents, New Zealand, Oral Health in Older Adults, Oral Healthcare, Oral Hygiene, P. gingivalis, Periodontitis, Periodontitis and Risk of Developing Alzheimer’s Disease, Poland, Porphyromonas gingivalis, Porphyromonas Gingivalis in Alzheimer’s Disease, Risk Factors, Science Advances (Journal), Small-Molecule Gingipain Inhibitors: Possibly Neuroprotective, Tau Tangles, Transgenic Mice, University of Auckland, University of California, University of Louisville School of Dentistry, University of Melbourne
Leave a comment
Preventative Treatment to Reduce Risk of Alzheimer’s Disease, Using Non-Steroidal Anti-Inflammatory Drugs? (NHS Choices / Journal of Alzheimer’s Disease)
Summary A recent article suggests that use of nonsteroidal anti-inflammatory drugs (NSAIDs) might help to reduce the risk of developing Alzheimer’s Disease, if prescription were to be commenced years before clinical signs were to develop. An NHS Choices Behind the … Continue reading
Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, Universal Interest
Tagged Aβ42, Alzheimer Disease Anti-Inflammatory Prevention, Alzheimer’s Disease Biomarkers, Amyloid Beta (Aβ42), Amyloid Beta Protein, Amyloid Cascade Inflammatory Hypothesis, Amyloid-β (Aβ), Amyloidogenic and Inflammatory Pathways, Aurin Biotech, Aurin Biotech Inc. Ltd. (Vancouver), ß-amyloid, Bazian, Behind the Headlines, Biomarkers, Canada, Critical Appraisals, Dementia Risk Reduction and Prevention, Dementia Saliva Testing (Pilot Study), Diagnosis of Alzheimer's Disease Based on Salivary Amyloid-β Protein 42 Levels, ELISA Method to Determine Aβ42 Levels in Saliva, Fluid Biomarker Analysis, Ibuprofen, Ibuprofen and the Reduced Risk of Alzheimer’s Disease Link, Inflammation, Journal of Alzheimer's Disease, Long-Term Ibuprofen Use, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Neuroinflammation, Non-Invasive Biomarkers, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), NSAIDS: Non-Steroidal Anti-Inflammatory Drugs, Preclinical Biomarkers in Alzheimer's Disease, Preventative Interventions, Prevention, Saliva Tests, Salivary Amyloid-β Protein 42 Levels, Salivary Biomarkers
Leave a comment
The Most Significant Breakthrough in the Treatment of Neurodegenerative Diseases in Fifty Years? (BBC News / UCL)
Summary An experimental drug for the treatment of Huntington’s Disease shows early signs of being able to lower the level of misfolded proteins (safely) in the brains of patients, thereby having the potential to slow or halt the progression of … Continue reading
Posted in BBC News, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Parkinson's Disease, Quick Insights, UK, Universal Interest
Tagged Alzheimer's Disease, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Antisense Oligonucleotides (ASO), Biomedical Research Centres (NIHR), Canada, Clinical Trial NCT02519036, Gene Silencing to Suppress Transcription and Translation of Huntingtin, Gene-Silencing, Genetic Research, Genetics, Germany, Huntingtin Protein, Huntingtin Protein (HTT), Huntington Disease, Huntington's Disease (HD): an Autosomal-Dominant Inherited Neurodegenerative Disorder, Huntington's Disease Centre: UCL Institute of Neurology, Huntington’s Disease, Ionis Pharmaceuticals, IONIS-HTTRx: Huntingtin-Lowering Drug, α-Synuclein, α-Synuclein Aggregation, Leonard Wolfson Experimental Neurology Centre (LWENC), Leonard Wolfson Experimental Neurology Centre: University College London, Misfolded Proteins, Mutant HTT (mHTT) Protein, Mutant Huntingtin (mHTT), National Institute for Health Research (NIHR), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neuronal Loss, Neuroprotection, Prof. Giovanna Mallucci, Professor Sarah Tabrizi: IONIS-HTTRx Global Chief Investigator, Professor Sarah Tabrizi: UCL Institute of Neurology, Protein Misfolding, Roche, Synucleinopathy, Tau, Tau Protein, Tauopathy, University College London (UCL), University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, University College London Hospitals NHS Foundation Trust / University College London (NIHR) Biomedical Research Centre
Leave a comment
Flashing Light: A Potential Alternative to Drug Treatment to Prevent Amyloid Plaque Formation? (BBC News / Nature)
Summary Animal research on genetically modified mice suggests that a specialised form of flashing light therapy might help slow the progression of Alzheimer’s Disease. It appears that shining a strobe light, flashing at a rate of 40Hz, into rodents’ eyes … Continue reading
Posted in Animal Studies, BBC News, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Non-Pharmacological Treatments, Quick Insights, Universal Interest
Tagged 40 Hz Light-Flickering Regime, Amyloid, Amyloid Beta, Amyloid Beta (Aβ42 and Aβ40), Amyloid Beta Protein, Amyloid Deposits, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Amyloid-β Protein, BBC Health News, Broad Institute of Harvard and MIT, Department of Brain and Cognitive Sciences: Massachusetts Institute of Technology, Departments of Biological Engineering and Brain and Cognitive Sciences: Massachusetts Institute of Technology, Flashing Light Therapy, Gamma Frequency Entrainment: Attenuation of Amyloid Load, Gamma Frequency Light, Gamma Light Oscillations (20-50 Hz), Gamma Rhythms, Immune Cells (Microglia), Institute of Medical Engineering and Sciences: Massachusetts Institute of Technology, Light Therapy, Light Therapy for Dementia, Massachusetts General Hospital (Boston), Massachusetts Institute of Technology, Massachusetts Institute of Technology (MIT), McGovern Institute for Brain Research: Massachusetts Institute of Technology, Mice, Microglia, MIT Media Lab: Massachusetts Institute of Technology, Nature, Non-Invasive 40 Hz Light-Flickering Regime, Picower Institute for Learning and Memory: Massachusetts Institute of Technology, Rodents, Strobe Light Therapy, Transgenic Mice, United States, USA
Leave a comment
